ATE508125T1 - Triazoloanilinopyrimidinderivate zur verwendung als antivirale mittel - Google Patents

Triazoloanilinopyrimidinderivate zur verwendung als antivirale mittel

Info

Publication number
ATE508125T1
ATE508125T1 AT07704895T AT07704895T ATE508125T1 AT E508125 T1 ATE508125 T1 AT E508125T1 AT 07704895 T AT07704895 T AT 07704895T AT 07704895 T AT07704895 T AT 07704895T AT E508125 T1 ATE508125 T1 AT E508125T1
Authority
AT
Austria
Prior art keywords
triazoloanilinopyrimidene
derivatives
antiviral agents
formula
prevention
Prior art date
Application number
AT07704895T
Other languages
English (en)
Inventor
Neil Mathews
Alexander Thomas
Keith Spencer
Nathalie Tiberghien
Christopher Pilkington
Lyn Jennens
Surinder Chana
Ian Fraser
Original Assignee
Arrow Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0600510A external-priority patent/GB0600510D0/en
Priority claimed from GB0612116A external-priority patent/GB0612116D0/en
Application filed by Arrow Therapeutics Ltd filed Critical Arrow Therapeutics Ltd
Application granted granted Critical
Publication of ATE508125T1 publication Critical patent/ATE508125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07704895T 2006-01-11 2007-01-11 Triazoloanilinopyrimidinderivate zur verwendung als antivirale mittel ATE508125T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0600510A GB0600510D0 (en) 2006-01-11 2006-01-11 Chemical compounds
GB0612116A GB0612116D0 (en) 2006-06-19 2006-06-19 Chemical Compounds
PCT/GB2007/000065 WO2007080401A1 (en) 2006-01-11 2007-01-11 Triazoloanilinopyrimidine derivatives for use as antiviral agents

Publications (1)

Publication Number Publication Date
ATE508125T1 true ATE508125T1 (de) 2011-05-15

Family

ID=37888130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07704895T ATE508125T1 (de) 2006-01-11 2007-01-11 Triazoloanilinopyrimidinderivate zur verwendung als antivirale mittel

Country Status (15)

Country Link
US (1) US20100158863A1 (de)
EP (1) EP1981876B1 (de)
JP (1) JP2009523163A (de)
KR (1) KR20080083139A (de)
AT (1) ATE508125T1 (de)
AU (1) AU2007204227B2 (de)
BR (1) BRPI0706412A2 (de)
CA (1) CA2635916A1 (de)
DE (1) DE602007014324D1 (de)
EC (1) ECSP088621A (de)
IL (1) IL191928A0 (de)
NZ (1) NZ569703A (de)
RU (1) RU2008132806A (de)
TW (1) TW200902515A (de)
WO (1) WO2007080401A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009214977A1 (en) * 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Heterocyclic derivatives as hepatitis C virus inhibitors
CN102552271B (zh) 2010-12-09 2014-08-06 中国科学院上海药物研究所 一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
JP2002521334A (ja) * 1998-07-20 2002-07-16 ブリストルーマイヤーズ スクイブ カンパニー 置換ベンズイミダゾール抗ウィルス剤
WO2001087845A2 (en) * 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
EP1748991A1 (de) * 2004-04-28 2007-02-07 Arrow Therapeutics Limited Morpholinylanilinochinazolinderivate zur verwendung als antivirale mittel
GB0501964D0 (en) * 2005-01-31 2005-03-09 Arrow Therapeutics Ltd Chemical compounds
US8143288B2 (en) * 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
GB0520475D0 (en) * 2005-10-07 2005-11-16 Arrow Therapeutics Ltd Chemical compounds

Also Published As

Publication number Publication date
DE602007014324D1 (de) 2011-06-16
BRPI0706412A2 (pt) 2011-03-29
KR20080083139A (ko) 2008-09-16
AU2007204227A1 (en) 2007-07-19
WO2007080401A1 (en) 2007-07-19
EP1981876B1 (de) 2011-05-04
WO2007080401A8 (en) 2008-07-24
CA2635916A1 (en) 2007-07-19
US20100158863A1 (en) 2010-06-24
IL191928A0 (en) 2008-12-29
TW200902515A (en) 2009-01-16
NZ569703A (en) 2011-07-29
ECSP088621A (es) 2008-08-29
AU2007204227B2 (en) 2011-03-03
JP2009523163A (ja) 2009-06-18
EP1981876A1 (de) 2008-10-22
RU2008132806A (ru) 2010-02-20

Similar Documents

Publication Publication Date Title
ATE524465T1 (de) 2-carboxy-thiophen-derivate als viruzide
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
EA200802213A1 (ru) Способы лечения заболеваний крови
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
MX374396B (es) Rocio de fentanilo sublingual.
WO2009026166A3 (en) Antiinfective flavonol compounds and methods of use thereof
NO20090628L (no) Pyridizinon derivativater
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
DE602005023015D1 (de) Indolderivate als viruzide
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
UA106367C2 (uk) Похідні азадиспіро[3.0.4.1]декану та їх застосування
MX2012006026A (es) Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
PH12012501630A1 (en) Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
DE602007014324D1 (de) Triazoloanilinopyrimidinderivate zur verwendung als antivirale mittel
TW200738651A (en) Cyclohexyl sulfonamide derivatives
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties